TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22227558

Group type: EXPERIMENTAL
Intervention: risperidone 6 mg/day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: haloperidol 20 mg/day
Number of subjects: 78

Group type: COMPARATOR
Intervention: normal controls
Number of subjects: 78
Study: 20206777

Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy (VBT) 21 Gy high-dose rate in three fractions or 30 Gy low-dose rate
Number of subjects: 427

Group type: COMPARATOR
Intervention: Pelvic external beam radiotherapy (EBRT) 46 Gy in 23 fractions
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: VBT
Number of subjects: 427

Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 427
Study: 17353459

Group type: EXPERIMENTAL
Intervention: 10-meter walk test at preferred speed
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 6-minute walk test at preferred speed
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 10-meter walk test at maximum speed
Number of subjects: 69

Group type: COMPARATOR
Intervention: 6-minute walk test
Number of subjects: 69
Study: 15652681

Group type: EXPERIMENTAL
Intervention: Organ donation education program
Number of subjects: 2868

Group type: COMPARATOR
Intervention: Control group (no education program)
Number of subjects: 2868
Study: 12020988

Group type: EXPERIMENTAL
Intervention: VTHR group (HR recorded at the gas exchange ventilatory threshold)
Number of subjects: 24

Group type: COMPARATOR
Intervention: KHR group (HR according to Karvonen formula)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 10454271

Group type: EXPERIMENTAL
Intervention: Breast milk (BM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Formula containing only 18-carbon polyunsaturated fatty acids (A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Formula enriched with long chain (LC) PUFA (B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Formula groups (A and B)
Number of subjects: 40
Study: 7598052

Group type: EXPERIMENTAL
Intervention: 15 mg beta-carotene
Number of subjects: 10
Study: 2378704

Group type: EXPERIMENTAL
Intervention: Pressure applied after injection of heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspiration of the syringe prior to injecting heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent injections with pressure applied after injection
Number of subjects: 0
Study: 627306

Group type: EXPERIMENTAL
Intervention: Disofrol (dexbrompheniramine maleate + d-isoephedrine sulphate)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lunerin (brompheniramine + 2-amino-1-phenyl-propanol-(1)-hydrochloride)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 29843238

Group type: EXPERIMENTAL
Intervention: Cognitive training (My Mind Project)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 321
Study: 27025688

Group type: EXPERIMENTAL
Intervention: Massage therapy to the quadriceps
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (resting in sitting)
Number of subjects: 74
Study: 24697702

Group type: EXPERIMENTAL
Intervention: Bathing Without a Battle intervention
Number of subjects: 240
Study: 23489856

Group type: EXPERIMENTAL
Intervention: Three one-hour curriculum sessions on consecutive days
Number of subjects: 197
Study: 19842168

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT) alone
Number of subjects: 63
Study: 19052401

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO) 500 mg capsules
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (300 mg sunflower oil capsules)
Number of subjects: 50
Study: 16895645

Group type: EXPERIMENTAL
Intervention: Intrauterine direct flushing of endometrial cavity with culture media (group 1)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cervical flushing without intrauterine flushing (group 2)
Number of subjects: 240
Study: 12804030

Group type: EXPERIMENTAL
Intervention: Stereo audio reproduction
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Six-channel audio reproduction
Number of subjects: 45

Group type: COMPARATOR
Intervention: Mono audio reproduction
Number of subjects: 45
Study: 10737700

Group type: EXPERIMENTAL
Intervention: Apomorphine (APO) stimulation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline administration
Number of subjects: 15
Study: 9184611

Group type: EXPERIMENTAL
Intervention: Nefazodone (200 mg/day for Days 1-7; 400 mg/day for Days 8-56)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day for Days 1-56)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both Nefazodone and Fluoxetine
Number of subjects: 44
Study: 8473650

Group type: EXPERIMENTAL
Intervention: RAMP
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: SCAN
Number of subjects: 29

Group type: COMPARATOR
Intervention: Unpaired trials
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 29
Study: 3513528

Group type: EXPERIMENTAL
Intervention: 1 mg guanfacine
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: 2 mg guanfacine
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: 3 mg guanfacine
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: 0.5 mg guanfacine
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 29166704

Group type: EXPERIMENTAL
Intervention: Visual impairment defined by presenting visual acuity less than or equal to 6/18 in the better eye
Number of subjects: 4106

Group type: EXPERIMENTAL
Intervention: Visual impairment defined by presenting visual acuity of 6/18 in at least one eye
Number of subjects: 4106

Group type: EXPERIMENTAL
Intervention: Visual impairment defined by presenting visual acuity of 6/12 in the worse eye
Number of subjects: 4106

Group type: EXPERIMENTAL
Intervention: Visual impairment defined by presenting visual acuity of 6/12 in the better eye
Number of subjects: 4106

Group type: EXPERIMENTAL
Intervention: Causes of visual impairment
Number of subjects: 4106

Group type: EXPERIMENTAL
Intervention: Distribution of visual impairment in children from low-income families
Number of subjects: 4106
Study: 26894832

Group type: EXPERIMENTAL
Intervention: 50 mm focal length
Number of subjects: 45

Group type: COMPARATOR
Intervention: 85 mm focal length
Number of subjects: 45

Group type: COMPARATOR
Intervention: 105 mm focal length
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Shorter focal lengths
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Overall facial shape analysis using GMM
Number of subjects: 45
Study: 24210070

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 67
Study: 23328421

Group type: EXPERIMENTAL
Intervention: Systemic education
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control
Number of subjects: 157
Study: 20805340

Group type: EXPERIMENTAL
Intervention: Subliminal processing of meaninglessness-related words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Threatened meaning
Number of subjects: 0
Study: 18194946

Group type: EXPERIMENTAL
Intervention: Behavior intervention, nutritional information and physical exercise
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study: 15726312

Group type: EXPERIMENTAL
Intervention: PSA-test and DRE advice
Number of subjects: 788
Study: 12854359

Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg tablet)
Number of subjects: 24
Study: 11101019

Group type: EXPERIMENTAL
Intervention: Extreme prematurity
Number of subjects: 132

Group type: COMPARATOR
Intervention: Full-term infants
Number of subjects: 132
Study: 8693619

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 1501568

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6648050

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31827352

Group type: EXPERIMENTAL
Intervention: Anode placement over the gluteal fold (GF)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Anode placement midway between the greater trochanter and the lower border of the iliac crest (Midtroc-iliac)
Number of subjects: 13
Study: 29219935

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine/morphine (12.5 mg/300 μg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham procedure and bolus of piritramide (0.1 mg/kg)
Number of subjects: 56
Study: 26962830

Group type: EXPERIMENTAL
Intervention: G(120-0) ≥ 2.50 mmol/L or G30 ≥ 9.75 mmol/L
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: High G(120-0) and high G30
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Diabetes nonconverters
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Diabetes converters
Number of subjects: 1126
Study: 24505327

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (conventional, diffusion tensor, and thalamic proton MR spectroscopy)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental outcomes assessed using Bayley III at 3½ years
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sarnat staging
Number of subjects: 54
Study: 22621162

Group type: EXPERIMENTAL
Intervention: 12% SDF + Peak SE
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 38% SDF + Peak SE
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 12% SDF + Peak LC
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 38% SDF + Peak LC
Number of subjects: 42

Group type: COMPARATOR
Intervention: Peak SE self‐etch bonding agent
Number of subjects: 42

Group type: COMPARATOR
Intervention: Peak LC etch‐and‐rinse bonding agent
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Self‐etch bonded teeth
Number of subjects: 42
Study: 20353111

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with rehabilitation techniques
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rehabilitation techniques only
Number of subjects: 60
Study: 17322481

Group type: EXPERIMENTAL
Intervention: Methodical style (33%)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Adaptive style (46%)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Inadequate style (21%)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Inadequate style
Number of subjects: 156
Study: 15883748

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 mg, bd, 14 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 40
Study: 12201566

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.3 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Lovastatin 20 mg
Number of subjects: 43
Study: 10442299

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 200 mg i.m. every 2 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7794981

Group type: EXPERIMENTAL
Intervention: Higher self-efficacy
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 79
Study: 1333518

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cyclophosphamide 400 mg/m2, doxorubicin 40 mg/m2, and cisplatin 40 mg/m2 for six cycles)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No active treatment (control group)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CAP)
Number of subjects: 110
Study: 4001254

Group type: EXPERIMENTAL
Intervention: Social-learning-based treatment
Number of subjects: 66
Study: 31509295

Group type: EXPERIMENTAL
Intervention: Alpine climate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate maritime climate treatment
Number of subjects: 0
Study: 29555622

Group type: EXPERIMENTAL
Intervention: Rehabilitation gaming group (n=29)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Entertainment gaming group (n=29)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Passive control group (n=32)
Number of subjects: 90
Study: 25777945

Group type: EXPERIMENTAL
Intervention: Mini Falls Assessment Instrument (MFAI) intervention
Number of subjects: 330

Group type: COMPARATOR
Intervention: Modified version not linked to actions (control)
Number of subjects: 330
Study: 24889392

Group type: EXPERIMENTAL
Intervention: L-ornithine (400 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 22273763

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 11
Study: 20424614

Group type: EXPERIMENTAL
Intervention: Internet support group after a lecture on the use of the Internet for support and information
Number of subjects: 921

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 921
Study: 18978403

Group type: EXPERIMENTAL
Intervention: Osteoporosis management initiated by the orthopaedic team in a specialized orthopaedic osteoporosis clinic
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care managed by primary care physician
Number of subjects: 62
Study: 15982429

Group type: EXPERIMENTAL
Intervention: Kinetic therapy (PediDyne bed)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard therapy (manual turning and percussion)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Kinetic therapy after standard therapy
Number of subjects: 50
Study: 12009344

Group type: EXPERIMENTAL
Intervention: Desogestrel (0.15 mg) plus Ethinyl Estradiol (0.030 mg) daily for 21 days followed by a 7-day rest for 12 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cyproterone Acetate (2 mg) plus Ethinyl Estradiol (0.035 mg) daily for 21 days followed by a 7-day rest for 12 months
Number of subjects: 28
Study: 9629401

Group type: EXPERIMENTAL
Intervention: Propranolol 60 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propranolol 60 mg/day plus Flunarizine 10 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All treatments (Propranolol, Flunarizine, Both)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Flunarizine (alone or associated with Propranolol)
Number of subjects: 45
Study: 8198246

Group type: EXPERIMENTAL
Intervention: Ophthalmic sodium cromoglycate 2% four times daily
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Ophthalmic sodium cromoglycate 4% twice daily
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo eye-drops twice daily
Number of subjects: 339
Study: 2454378

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propranolol 80 mg x 2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carvedilol (both doses)
Number of subjects: 30
Study: 29090475

Group type: EXPERIMENTAL
Intervention: Intense method for plaque control - daily powered tooth brushing with 1% Chlorhexidine gel
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional method for plaque control - daily manual tooth brushing with a standardised commercial toothpaste
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both interventions (Conventional and Intense)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Baseline plaque levels
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Baseline functional dependency level
Number of subjects: 86
Study: 28595700

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 25432220

Group type: EXPERIMENTAL
Intervention: Heliox
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air-oxygen
Number of subjects: 0
Study: 22247303

Group type: EXPERIMENTAL
Intervention: HCMV-positive infants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCMV-positive HIV-exposed infants
Number of subjects: 0
Study: 19941334

Group type: EXPERIMENTAL
Intervention: General Health Questionnaire at 3, 6, and 12 months
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sickness Impact Profile at 3, 6, and 12 months
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies Depression Scale at 3, 6, and 12 months
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Treatment of muscle ache and cramps
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Perception of physical residua
Number of subjects: 85
Study: 18976032

Group type: EXPERIMENTAL
Intervention: Attention deficit hyperactivity disorder symptoms screening
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Hyperactive-impulsive type of attention deficit hyperactivity
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Combined type of attention deficit hyperactivity
Number of subjects: 2000
Study: 16620266

Group type: EXPERIMENTAL
Intervention: Isocaloric low-fat diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard diabetes diet
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 13
Study: 12853344

Group type: EXPERIMENTAL
Intervention: VAD bolus (vincristine 0.4 mg i.v., doxorubicin 9 mg/m² i.v., dexamethasone 40 mg p.o. daily for 4 days)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: VAD doxil (vincristine 2 mg i.v., liposomal doxorubicin 40 mg/m² i.v. on day 1, dexamethasone 40 mg p.o. daily for 4 days)
Number of subjects: 259

Group type: COMPARATOR
Intervention: VAD bolus
Number of subjects: 259

Group type: COMPARATOR
Intervention: VAD doxil
Number of subjects: 259
Study: 11148800

Group type: COMPARATOR
Intervention: Fluoride therapy
Number of subjects: 1429
Study: 8823827

Group type: EXPERIMENTAL
Intervention: QT = ACT dual sensor VVIR mode
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Low ACT threshold dual sensor mode
Number of subjects: 4

Group type: COMPARATOR
Intervention: QT only VVIR mode
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Optimally programmed ACT setting
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Low threshold ACT setting
Number of subjects: 4
Study: 8504233

Group type: EXPERIMENTAL
Intervention: Program A (guided by pain)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Program B (intensive physical training, 'no pain, no gain')
Number of subjects: 309

Group type: COMPARATOR
Intervention: Both programs
Number of subjects: 309
Study: 3959249

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Propantheline
Number of subjects: 34
Study: 29458904

Group type: EXPERIMENTAL
Intervention: Dysmenorrhea group
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Dysmenorrhea group with vitamin D deficiency
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency group
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Dysmenorrhea patients
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study: 26836220

Group type: EXPERIMENTAL
Intervention: Flexible duty-hour policies
Number of subjects: 4330

Group type: COMPARATOR
Intervention: Standard duty-hour policies
Number of subjects: 4330
Study: 25480673

Group type: EXPERIMENTAL
Intervention: Shenyankangfu tablets
Number of subjects: 720

Group type: COMPARATOR
Intervention: losartan potassium 50 mg
Number of subjects: 720

Group type: COMPARATOR
Intervention: losartan potassium 100 mg
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Shenyankangfu tablets + losartan potassium 50 mg
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Shenyankangfu tablets + losartan potassium 100 mg
Number of subjects: 720
Study: 22244574

Group type: EXPERIMENTAL
Intervention: 10mg escitalopram
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 20145261

Group type: EXPERIMENTAL
Intervention: Fenofibric acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 0
Study: 17715211

Group type: EXPERIMENTAL
Intervention: VML-670 (5-HT(1A) and 5-HT(1D) agonist)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: VML-670
Number of subjects: 288
Study: 15956360

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (E2)
Number of subjects: 0
Study: 12528088

Group type: EXPERIMENTAL
Intervention: Carvedilol (37.5 +/- 13.5 mg/12 h)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bisoprolol (5.4 +/- 3.0 mg/d)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 26
Study: 10736887

Group type: EXPERIMENTAL
Intervention: Integrated medical‐dental patient‐held record (PHR) issued to patients
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Integrated medical‐dental patient‐held record (PHR)
Number of subjects: 369
Study: 7537286

Group type: EXPERIMENTAL
Intervention: Risperidone 6 to 16 mg/day
Number of subjects: 135

Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day
Number of subjects: 135
Study: 2042757

Group type: EXPERIMENTAL
Intervention: Alfentanil infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketamine infusion
Number of subjects: 60
Study: 45068

Group type: EXPERIMENTAL
Intervention: Oxytocin induced labor using amniotomy and oxytocin infusion with the Cardiff Infusion System Mark II
Number of subjects: 84

Group type: COMPARATOR
Intervention: Spontaneous labor
Number of subjects: 84
Study: 30855082

Group type: EXPERIMENTAL
Intervention: In-person support intervention
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Remote support intervention
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 415
Study: 31771714

Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28081548

Group type: EXPERIMENTAL
Intervention: Continuation of bevacizumab with second-line chemotherapy
Number of subjects: 184
Study: 26175145

Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate citrate (FPC, Triferic™) via hemodialysate
Number of subjects: 599

Group type: COMPARATOR
Intervention: Standard dialysate (placebo)
Number of subjects: 599
Study: 23374649

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting biodegradable polymer stent
Number of subjects: 2468

Group type: COMPARATOR
Intervention: Sirolimus-eluting permanent polymer stent
Number of subjects: 2468